CSIMarket
 
Tracon Pharmaceuticals Inc   (TCON)
Other Ticker:  
 
 
Price: $0.0322 $0.00 0.000%
Day's High: $0.04 Week Perf: 0.00
Day's Low: $ 0.03 30 Day Perf: 9.15 %
Volume (M): 15 52 Wk High: $ 14.75
Volume (M$): $ 0 52 Wk Avg: $1.60
Open: $0.04 52 Wk Low: $0.02



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 3
 Employees 43
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Tracon Pharmaceuticals Inc
Tracon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of targeted therapies for cancer and other diseases. The company's main areas of research include immuno-oncology, tissue factor targeting, and adenosine signaling. Tracon aims to develop innovative drugs that can improve the treatment outcomes for patients with unmet medical needs. The company collaborates with various partners and utilizes advanced technologies to bring its pipeline of potential therapies to the market.


   Company Address: 4350 La Jolla Village Drive San Diego 92122 CA
   Company Phone Number: 550-0780   Stock Exchange / Ticker: TCON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRDF        7.26% 
FATE   -11.97%    
GRTS   -53.06%    
INTS        2.65% 
IOVA   -8.43%    
NKGN   -21.43%    
• View Complete Report
   



Stock Market Announcement

TRACON Pharmaceuticals Terminates Employees and Winding Down Operations, Share Price Plummets

Published Tue, Jul 30 2024 8:45 PM UTC


In a shocking turn of events, TRACON Pharmaceuticals announced the termination of its employees and the winding down of its operations. This decision was reached at a special meeting of the board of directors, sending shockwaves through the pharmaceutical industry and leaving shareholders reeling.
The impact on shareholders has been immediate and devastating. TRACON...

Clinical Study

Termination of ENVASARC Trial Marks Turning Point for TRACON Pharmaceuticals

Published Mon, Jul 1 2024 1:00 PM UTC

In a recent announcement, TRACON Pharmaceuticals revealed the termination of its ENVASARC trial due to unsatisfactory results. This decision has prompted the company to explore strategic alternatives while harnessing its in-house product development platform. With the response rate falling short of the primary endpoint, TRACON Pharmaceuticals now faces a critical juncture i...

Stocks on the Move

Tracon Pharmaceuticals Inc Underperforms Market, Faces Executive Departure

Published Thu, Jun 27 2024 5:23 PM UTC

Tracon Pharmaceuticals Inc, a San Diego-based company specializing in biological products, has experienced a lackluster performance compared to the overall market. This article aims to provide an analysis of the company s recent financial performance and its potential implications, with a particular focus on interpreting two relevant articles published on June 20, 2024, and...

Clinical Study

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced encouraging findings published in the peer-review...

Published Tue, Jun 11 2024 12:00 PM UTC

Promising New Data on TRC102 in Recurrent Glioblastoma: Enhancing Temodar Efficacy TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced encouraging findings published in the peer-reviewed journal Clinical Cancer Research showcasing the efficacy of TRC102 in Phase 2 clinical trials involving recurrent glioblastoma patients. This study highlights the synergy between TRC10...

Shares

TRACON Pharmaceuticals Takes Bold Step with Reverse Stock Split to Enhance Market Position

Published Mon, Apr 8 2024 1:10 PM UTC

TRACON Pharmaceuticals Implements Reverse Stock Split to Strengthen Position in Biopharmaceutical Market
In the fast-paced and competitive world of biopharmaceuticals, companies must constantly adapt and evolve to meet the demands of investors and stakeholders. TRACON Pharmaceuticals, a clinical stage biopharmaceutical company based in San Diego, recently made a bold mov...







Tracon Pharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com